Trials / Completed
CompletedNCT00002237
A Study of Peldesine (BCX-34) in HIV-Infected Patients
Phase I Placebo-Controlled Study of Oral BCX-34 (Peldesine) in HIV-Infected Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.
Detailed description
Patients are given either BCX-35 or placebo for 14 or 28 days. Plasma viral load will be determined at the MTD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peldesine |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002237. Inclusion in this directory is not an endorsement.